Myeloma bone disease: from biology findings to treatment approaches

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 133; no. 14; pp. 1534 - 1539
Main Authors Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Dimopoulos, Meletios A.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 04.04.2019
Subjects
Bone Diseases - drug therapy
Bone Diseases - etiology
Denosumab - therapeutic use
Humans
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Osteocytes - pathology
Online AccessGet full text

Cover

More Information
Summary:Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood-2018-11-852459